Cirtuvivint

DB17269InvestigationalSmall molecule

Cirtuvivint is a first-in-class CDC-like kinase (CLK) inhibitor.

Mechanism: Pharmacologically active on Dual specificity protein kinase CLK1, Dual specificity tyrosine-phosphorylation-regulated kinase 1A, and Dual specificity protein kinase CLK3
Curator reviewed
Formula / weight: C₂₄H₂₅N₇O · 427.512 g/mol (avg)
Also known as: 4-pyridinecarboxamide, 2-(4-methyl-1-piperazinyl)-n-(6-(1-methyl-1h-pyrazol-4-yl)-3-isoquinolinyl)- · CDC-like kinase inhibitor of the Wnt Pathway
Code names: SM-08502

Resolves to

Compound

Structure

InChIKeyBQWWOBKMDWACGC-UHFFFAOYSA-NSMILESCN1C=C(C=N1)C1=CC2=C(C=C1)C=NC(NC(=O)C1=CC=NC(=C1)N1CCN(C)CC1)=C2

Targets

What you can answer from here — as of July 08, 2026

9Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cirtuvivint, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.